Development
Sarepta Therapeutics, Inc.
SRPT
$16.26
-$0.49-2.93%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 211.53% | -71.00% | 95.37% | -373.03% | 57.61% |
| Total Depreciation and Amortization | 4.06% | 1.26% | -4.54% | 7.13% | -1.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -44.86% | 212.83% | -114.60% | 636.86% | -66.47% |
| Change in Net Operating Assets | 2.86% | -228.96% | 63.56% | -151.12% | -614.65% |
| Cash from Operations | 52.35% | 6.16% | 41.63% | -126.64% | -42.22% |
| Capital Expenditure | 35.84% | -65.69% | -88.81% | -19.10% | 3.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 74.95% | -257.93% | 421.19% | 23.74% | -35.06% |
| Cash from Investing | 69.44% | -317.91% | 673.57% | 27.52% | -48.76% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -87.39% | 162.84% | -79.10% | 148.05% | -15.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | 13,413.72% | 99.45% |
| Cash from Financing | -87.39% | 162.84% | -94.24% | 847.02% | -95.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 62.22% | -1,469.85% | 79.25% | -32.38% | -142.12% |